食管癌围术期治疗的争议与共识

食管癌是全球排名第七的恶性肿瘤，在癌症相关的死亡原因中排名第六。手术治疗是可切除食管癌的主要治疗方式，但对于局部晚期食管癌患者，单纯手术治疗后，局部复发和远处转移缩短了患者的生存期，因此除极早期肿瘤外，所有患者推荐术前行新辅助放化疗或新辅助化疗。但是仍然有一部分患者未能在术前行新辅助治疗，这就需要术后辅助治疗来改善患者预后。本文系统回顾了食管癌围术期治疗的研究进展，包括新辅助治疗和辅助治疗，并结合指南对食管癌围术期的治疗方案进行了总结。

Controversy and consensus on perioperative treatment of esophageal cancer

Esophageal cancer is the seventh malignant tumor in the world and the sixth leading cause of cancer-related death.Surgical treatment is the main treatment for resectable esophageal cancer,but for patients with locally advanced esophageal cancer,local recurrence and metastasis greatly shorten the survival time after surgical treatment alone,so except for very early tumors,all patients are recommended to receive neoadjuvant radiotherapy and chemotherapy or neoadjuvant chemotherapy before operation.However,there are still some patients who fail to receive neoadjuvant therapy before operation,so postoperative adjuvant therapy is needed to improve the prognosis of patients.This paper systematically reviews the research progress of perioperative treatment of esophageal cancer,including neoadjuvant therapy and adjuvant therapy,and summarizes the perioperative treatment of esophageal cancer combined with guidelines.